诺氟沙星在人体肾脏和前列腺组织中的渗透情况。
Norfloxacin penetration into human renal and prostatic tissues.
作者信息
Bergeron M G, Thabet M, Roy R, Lessard C, Foucault P
出版信息
Antimicrob Agents Chemother. 1985 Aug;28(2):349-50. doi: 10.1128/AAC.28.2.349.
Abstract
Concurrent norfloxacin concentrations in serum, kidney, and prostatic tissue were determined in 14 patients. Mean ratios of norfloxacin concentration in tissue over concentration in serum were 6.6 +/- 2.8 for the kidney and 1.7 +/- 0.2 for the prostate samples. The levels were above the MICs of most urinary pathogens.
摘要
对14例患者的血清、肾脏和前列腺组织中的诺氟沙星浓度进行了同步测定。肾脏中诺氟沙星组织浓度与血清浓度的平均比值为6.6±2.8，前列腺样本的该比值为1.7±0.2。这些水平高于大多数尿路病原体的最低抑菌浓度。
相似文献
1
Norfloxacin penetration into human renal and prostatic tissues.诺氟沙星在人体肾脏和前列腺组织中的渗透情况。
Antimicrob Agents Chemother. 1985 Aug;28(2):349-50. doi: 10.1128/AAC.28.2.349.
2
Differentiated distribution of norfloxacin in the medullary-cortical part of the kidney in man.诺氟沙星在人体肾脏髓质 - 皮质部分的差异分布。
Int J Clin Pharmacol Res. 1986;6(5):351-4.
3
Penetration of norfloxacin into human prostatic tissue following single-dose oral administration.
Chemotherapy. 1987;33(4):240-2. doi: 10.1159/000238501.
4
Study on pulmonary, prostatic and renal (medulla and cortex) distribution of sagamicin at different time intervals.不同时间间隔下相模霉素在肺、前列腺及肾（髓质和皮质）中的分布研究。
Int J Clin Pharmacol Res. 1987;7(1):51-8.
5
Gentamicin concentrations in blood, urine, and renal tissue of patients with end-stage renal disease.终末期肾病患者血液、尿液和肾组织中的庆大霉素浓度。
J Lab Clin Med. 1977 Aug;90(2):389-93.
6
Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
J Formos Med Assoc. 2001 Aug;100(8):548-52.
7
Concentrations of norfloxacin in prostatic tissues following oral administration in patients with benign prostatic hyperplasia.
Int Urol Nephrol. 1988;20(1):47-9. doi: 10.1007/BF02583030.
8
[Norfloxacin concentration in human prostatic tissue after 3 days administration].3天给药后人体前列腺组织中的诺氟沙星浓度
Hinyokika Kiyo. 1989 Jul;35(7):1261-5.
9
Concentration of gentamicin in serum, urine and urogenital tissue in man.
Acta Pathol Microbiol Scand B Microbiol Immunol. 1973:Suppl 241:92-4.
10
Distribution of quinoline carboxylic acid derivatives in the dog prostate.喹啉羧酸衍生物在犬前列腺中的分布。
Prostate. 1983;4(4):407-14. doi: 10.1002/pros.2990040411.
引用本文的文献
1
Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.喹诺酮类药物作为泌尿生殖系统癌症治疗的潜在药物——文献综述
Front Oncol. 2022 Jun 8;12:890337. doi: 10.3389/fonc.2022.890337. eCollection 2022.
2
Pharmacologic Basis for the Treatment of Pyelonephritis.肾盂肾炎治疗的药理学基础
Curr Infect Dis Rep. 1999 Oct;1(4):371-378. doi: 10.1007/s11908-999-0044-0.
3
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.诺氟沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1985 Dec;30(6):482-513. doi: 10.2165/00003495-198530060-00003.
4
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.新型抗菌4-喹诺酮类药物的临床药代动力学
Clin Pharmacokinet. 1988 Feb;14(2):96-121. doi: 10.2165/00003088-198814020-00003.
5
Enoxacin penetration into human prostatic tissue.依诺沙星在人前列腺组织中的渗透情况。
Antimicrob Agents Chemother. 1988 Sep;32(9):1433-4. doi: 10.1128/AAC.32.9.1433.
6
Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.氟罗沙星（Ro 23 - 6240）在犬前列腺组织和体液中的分布。
Antimicrob Agents Chemother. 1987 Jul;31(7):1010-3. doi: 10.1128/AAC.31.7.1010.
7
Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.氟喹诺酮类抗生素。微生物学、药代动力学及临床应用。
Drugs. 1988 Aug;36(2):193-228. doi: 10.2165/00003495-198836020-00004.
8
Quinolone antibacterial agents for the treatment of genitourinary tract infections.用于治疗泌尿生殖道感染的喹诺酮类抗菌剂。
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1111-6. doi: 10.1007/BF01975178.
9
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
10
Pharmacokinetic disposition of quinolones in human body fluids and tissues.
Clin Pharmacokinet. 1989;16 Suppl 1:5-24. doi: 10.2165/00003088-198900161-00004.
本文引用的文献
1
Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.诺氟沙星：对尿路病原体的活性及影响耐药性产生的因素
J Antimicrob Chemother. 1984 Apr;13(4):315-23. doi: 10.1093/jac/13.4.315.
2
The pharmacokinetics and tissue penetration of norfloxacin.诺氟沙星的药代动力学及组织穿透性。
J Antimicrob Chemother. 1984 Jan;13(1):87-92. doi: 10.1093/jac/13.1.87.
3
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.诺氟沙星（MK - 0366）治疗住院患者尿路感染
J Antimicrob Chemother. 1983 Jun;11(6):589-92. doi: 10.1093/jac/11.6.589.
4
Bioassay procedures for norfloxacin.
Eur J Clin Microbiol. 1983 Jun;2(3):249-52. doi: 10.1007/BF02029527.
5
Norfloxacin disposition after sequentially increasing oral doses.依次增加口服剂量后诺氟沙星的处置情况。
Antimicrob Agents Chemother. 1983 Feb;23(2):284-8. doi: 10.1128/AAC.23.2.284.
6
Antibacterial activity of norfloxacin.诺氟沙星的抗菌活性。
Antimicrob Agents Chemother. 1983 Jan;23(1):15-8. doi: 10.1128/AAC.23.1.15.
7
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸类药物诺氟沙星的体外活性与β-内酰胺类、氨基糖苷类及甲氧苄啶的比较。
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
8
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗非复杂性社区获得性尿路感染的疗效比较
Antimicrob Agents Chemother. 1985 Mar;27(3):422-3. doi: 10.1128/AAC.27.3.422.
9
Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.诺氟沙星与甲氧苄啶-磺胺甲恶唑治疗尿路感染的多中心比较研究。
Antimicrob Agents Chemother. 1985 Mar;27(3):297-301. doi: 10.1128/AAC.27.3.297.
10
Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution.单次或多次剂量庆大霉素和奈替米星对其在皮质、髓质和乳头体分布的影响。
Antimicrob Agents Chemother. 1979 May;15(5):635-41. doi: 10.1128/AAC.15.5.635.
Zotero 插件